NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.32 -0.06 (-0.08%) GOLD FUTURES
2,323.80 -0.40 (-0.02%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
49,987.01 -583.59 (-1.15%)
BEAM Oct 2024 30.000 call
| Previous close | 3.0000 |
| Open | 3.0000 |
| Bid | 1.7000 |
| Ask | 2.1500 |
| Strike | 30.00 |
| Expiry date | 2024-10-18 |
| Day's range | 3.0000 - 3.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
GlobeNewswireBeam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM-301 On Track for Submission of U.S. Investigational New Drug (IND) Application in First Half of 2024 Ended First Quarter 2024 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities;
ZacksUltragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.02% and 4.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksBeam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Beam Therapeutics (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
